Effect of Letrozol in cell proliferation marker of breast cancer patients

Evaluation of Ki67 factor changes after 7 days treatment with Letrozol in postmenopausal women with an early stage breast cancer and hormone receptor positive

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20101104005101N2

Enrollment

Registered

2022-05-10

Start date

2020-02-25

Completion date

Unknown

Last updated

2022-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer. Malignant neoplasm of breast

Interventions

Intervention 1: Intervention group: Prescription of Letrozol tablet (IRAN HORMONE PHRAMACEUTICAL CO.) 2.5 mg/day for 1 week before surgery and comparison of Ki67% level before and after drug consumpti

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Breast caner patients Early stage of disease With hormone receptor positive Postmenopausal women

Exclusion criteria

Exclusion criteria: Metastatic breast cancer Premenopausal women Other sub-types of breast cancer

Design outcomes

Primary

Measure	Time frame
Cell proliferation factor (Ki67). Timepoint: Measurement of ki67% level at the beginning of the study (before intervention) and one week after using Letrozol tablet. Method of measurement: Ki-67 will be calculated using scoring systems to estimate a proliferation index (PI); the number of positively stained tumor nuclei divided by the total number of nuclei in a specific region by pathologists.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRamesh Omranipour

Tehran University of Medical Sciences

omranipour@tums.ac.ir+98 21 6119 2761

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026